Hikma Pharmaceuticals Plc Hikma receives favourable court ruling (9913X)
03 Settembre 2020 - 4:15PM
UK Regulatory
TIDMHIK
RNS Number : 9913X
Hikma Pharmaceuticals Plc
03 September 2020
Hikma receives favourable court ruling for its generic Vascepa
(R)
London, September 3, 2020 - Hikma Pharmaceuticals PLC (Hikma),
the multinational pharmaceutical company, announces that the US
Court of Appeals for the Federal Circuit today upheld a ruling by
the US District Court for the District of Nevada finding that
Hikma's generic version of Vascepa(R)1 (icosapent ethyl) 1gm does
not infringe any valid claim of six key Amarin-owned patents. Hikma
received FDA approval for the product in May 2020 and is working
towards a launch.
Vascepa(R) is a prescription medicine that is indicated, in
part, as an adjunct to diet to reduce triglyceride levels in adult
patients with severe (>= 500 mg/dL) hypertriglyceridemia.
According to IQVIA, US sales of Vascepa(R) were approximately $1.1
billion in the 12 months ending July 2020.
"We are very pleased with the Federal Circuit's swift decision
and to be one step closer to launching a generic version of this
important medicine for US patients and healthcare providers,
helping us to continue putting better health, within reach, every
day," said Brian Hoffmann, President of Hikma Generics. "Today's
decision demonstrates Hikma's ability to successfully challenge
patents on important medicines and to provide value to our
customers and millions of patients across the United States."
(1) Vascepa(R) is a registered trademark of Amarin
Pharmaceuticals Ireland Limited
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global Affairs 477050
uk-investors@hikma.uk.com
Steve Weiss +1 732 720 2830/ +1 732 788
David Belian 8279
US Communications and Public Affairs +1 732 720 2814/ +1 848 254
4875
u scommunications @hikma.com
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and Ba1/stable Moody's)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUPGBUPUGCW
(END) Dow Jones Newswires
September 03, 2020 10:15 ET (14:15 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024
